Hao Nguyen, MD, PhD

Genitourinary cancer specialist

Dr. Hao Nguyen is a urologic oncologist at the UCSF Helen Diller Family Comprehensive Cancer Center. He specializes in the early detection, diagnosis and treatment of prostate cancer, kidney cancer, bladder cancer and other genitourinary cancers. He performs open, robotic, laparoscopic and endoscopic surgeries.

Nguyen earned a bachelor's degree in molecular cell biology from UC Berkeley in 1999. To further his training as a physician scientist, he then joined the M.D.–Ph.D. program at Boston University School of Medicine's Department of Biochemistry and Molecular Medicine. He completed his general surgery and urologic surgery training at UC Davis, followed by a fellowship in urologic oncology at UCSF, under the guidance of Dr. Peter Carroll and Dr. Maxwell Meng. At the end of his fellowship, Nguyen joined the faculty at the UCSF Department of Urology, where he is an assistant adjunct professor.

Nguyen has authored more than 25 peer-reviewed scientific articles and book chapters and has been invited to present his research findings at national conferences. In 2015, he received the prestigious Department of Defense Physician Research Training Award to continue his research on how cancer cells are able to survive cancer treatments via a mechanism known as the stress response. His hope is that his findings will lead to new treatments that target this response.

Nguyen is an active member of the American Urological Association and the American Society of Clinical Oncology.


Prostate Cancer Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Medical Oncology Phone: (415) 476-4616
Surgical Oncology Phone: (415) 353-7171
Medical Oncology Fax: (415) 353-7107
Surgical Oncology Fax: (415) 514-6195

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgical Oncology Clinic
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
New Patient Fax: (415) 514-6195
General Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Academic Title

Assistant Professor

More about Hao Nguyen


Boston University School of Medicine 2007


UC Davis Medical Center, General Surgery and Urologic Surgery 2013


UCSF Medical Center, Urologic Oncology 2015

Selected Research and Publications

  1. Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol. 2018 Feb 20; 36(6):581-590.
  2. Nguyen HG, Welty C, Lindquist K, Ngo V, Gilbert E, Bengtsson H, Magi-Galluzzi C, Jean-Gilles J, Yao J, Cooperberg M, Messing E, Klein EA, Carroll PR, Paris PL. Validation of GEMCaP as a DNA based biomarker to predict prostate cancer recurrence after radical prostatectomy. J Urol. 2017 Sep 20.
  3. Garcia-Reyes K, Nguyen HG, Zagoria RJ, Shinohara K, Carroll PR, Behr SC, Westphalen AC. Impact of lesion visibility on transrectal ultrasound on the prediction of clinically significant prostate cancer (Gleason score = 3+4) with TRUS-MRI fusion biopsy. J Urol. 2017 Sep 20.
  4. Leapman MS, Cowan JE, Nguyen HG, Shinohara KK, Perez N, Cooperberg MR, Catalona WJ, Carroll PR. Active Surveillance in Younger Men With Prostate Cancer. J Clin Oncol. 2017 Jun 10; 35(17):1898-1904.
  5. Nguyen HG, Punnen S, Cowan JE, Leapman M, Cary C, Welty C, Weinberg V, Cooperberg MR, Meng MV, Greene KL, Garcia M, Carroll PR. A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. J Urol. 2017 Feb; 197(2):369-375.
  6. Tran GN, Leapman MS, Nguyen HG, Cowan JE, Shinohara K, Westphalen AC, Carroll PR. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance. Eur Urol. 2017 Aug; 72(2):275-281.
  7. Choi JY, Yang J, Noworolski SM, Behr S, Chang AJ, Simko JP, Nguyen HG, Carroll PR, Kurhanewicz J, Seo Y. 18F Fluorocholine Dynamic Time-of-Flight PET/MR Imaging in Patients with Newly Diagnosed Intermediate- to High-Risk Prostate Cancer: Initial Clinical-Pathologic Comparisons. Radiology. 2017 Feb; 282(2):429-436.
  8. Leapman MS, Ameli N, Shinohara K, Nguyen HG, Meng MV, Cooperberg MR, Carroll PR. Validity of the Cancer of the Prostate Risk Assessment Score Derived From Targeted Biopsy: Modeling Evidence From Ultrasound Lesion-Directed Biopsy. Clin Genitourin Cancer. 2017 Feb; 15(1):93-99.
  9. Leapman MS, Nguyen HG, Cooperberg MR. Clinical Utility of Biomarkers in Localized Prostate Cancer. Curr Oncol Rep. 2016 May; 18(5):30.
  10. Leapman MS, Nguyen HG. Editorial Comment. Urology. 2016 07; 93:84-5.
  11. Hsieh AC, Nguyen HG, Wen L, Edlind MP, Carroll PR, Kim W, Ruggero D. Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. Sci Signal. 2015 Nov 17; 8(403):ra116.
  12. Shi XB, Ma AH, Xue L, Li M, Nguyen HG, Yang JC, Tepper CG, Gandour-Edwards R, Evans CP, Kung HJ, deVere White RW. miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. Cancer Res. 2015 Dec 15; 75(24):5309-17.
  13. Sheridan CM, Grogan TR, Nguyen HG, Galet C, Rettig MB, Hsieh AC, Ruggero D. YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence. Oncotarget. 2015 Apr 10; 6(10):7470-80.
  14. Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Espinós EL, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. J Urol. 2015 Aug; 194(2):304-308.
  15. Nguyen HG, Welty CJ, Cooperberg MR. Diagnostic associations of gene expression signatures in prostate cancer tissue. Curr Opin Urol. 2015 Jan; 25(1):65-70.
  16. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015 Mar; 193(3):807-11.
  17. Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy. J Urol. 2015 Feb; 193(2):436-42.
  18. Martínez-Salamanca JI, Linares E, González J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, Shariat SF, Spahn M, Terrone C, Tilki D, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Curr Urol Rep. 2014 May; 15(5):404.
  19. Shinohara K, Nguyen H, Masic S. Management of an increasing prostate-specific antigen level after negative prostate biopsy. Urol Clin North Am. 2014 May; 41(2):327-38.
  20. Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN, DeVere White RW, Gao AC, Evans CP. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014 Sep 04; 33(36):4521-30.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.